Investigators at the National Cancer Institute (NCI) have discovered an adjuvanted mucosal subunit vaccine to prevent SARS-CoV-2 transmission and infection. The mucosal vaccine is composed of a novel molecular adjuvant nanoparticle that induces robust humoral and cellular immunity, as well as trained innate immunity with enhanced protection against respiratory SARS-CoV-2 exposure. The technology is available for potential licensing or collaborative research to co-develop these therapeutic targets.
Researchers at the National Cancer Institute (NCI) developed improved monospecific and bicistronic chimeric antigen receptors (CARs) targeting CD19 and CD20. Importantly, CD19 and CD20 are highly expressed in diffuse large B-cell lymphoma, acute lymphoblastic leukemia and other B-cell lymphomas. These improved CARs can be useful in treating these diseases. NCI is seeking parties interested in the co-development or licensing of this invention for immunotherapy.
Researchers at the National Cancer Institute developed a combination immunotherapy using Glypican-3 (GPC3)-targeted chimeric antigen receptor (CAR) T cells and a recombinant IL-7 drug for the treatment of hepatocellular carcinoma (HCC).
The thymus is the only organ capable of producing conventional, mature T cells; a crucial part of the adaptive immune system. However, its efficiency and function are progressively reduced as we age, leading to a compromised immune system in the elderly. Moreover, production of T cells with specific receptors is an important concern for cancer immunotherapy. Current in vitro methods produce immature T cells that are not useful for therapy. Researchers at the National Cancer Institute (NCI) have generated an autologous thymic organoid from human pluripotent stem cells to address this problem. The organoid can be used to develop clinical applications such as production of autologous T and natural killer T (NKT) cells and reconstitution of the adaptive immune system. NCI is seeking licensees for the thymic organoid and the method of its generation to be used in a variety of clinical applications.
Multi-potential hematopoietic progenitor cells (HPC) can differentiate into any class of blood cells, and are highly useful in regenerative medicine, immunology, and cancer immunotherapy. Current methods to generate HPCs are limited either due to the use of animal products, or the high cost and low efficiency of animal product free systems. Researchers at the National Cancer Institute (NCI) have developed a protocol to prepare HPCs from human induced pluripotent stem cells (hiPSC), using human mesenchymal stem cells (hMSC) in a three-dimensional (3D) co-culture condition. Thus, they are able to generate HPCs in a fully human, autologous system, which can be used to further generate immune cells for therapy. This protocol is adaptable to mass production by bioreactors. NCI seeks licensees for these methods of generating HPCs in a 3D co-culture with hMSCs to be used in a variety of applications such as treatment of blood disorders, regenerative medicine, and antibody production.
Scientists at the National Cancer Institute (NCI) have developed a novel delivery platform in which the scaffold of an anionic hydrogel (AcVES3) can be attenuated to deliver therapeutic small molecules, peptides, proteins, nanoparticles, or whole cells. The NCI seeks collaborators and licensees for the development of this technology in various clinical and laboratory applications.
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for the sulfatide analog, C24:2, that is capable of activating tumor killing type II NKT cells and reducing cancer metastasis to the lung.
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for further development of novel iodonium analogs. These iodonium analogs inhibit NADPH oxidases (NOX) and other flavin dehydrogenases to slow tumor growth.
Researchers at the University of California, Irvine (UCI) and NCI seek licensing for a new family of far-red to near-infrared emission coumarin-based luciferins (CouLuc) with complementary mutant enzymes.
IFN-gamma and IL-10 are cytokine signaling molecules that play fundamental roles in inflammation, cancer growth and autoimmune diseases. Unfortunately, there are no specific inhibitors of IFN-gamma or IL-10 on the market to date. The National Cancer Institute seeks parties interested in licensing or collaborative research to co-develop selective IL-10 and IFN-gamma peptide inhibitors.
Tuberculosis (TB) is an infectious disease that typically affects the lungs. Current therapies include a panel of antibiotics given over a range of 6-9 months. As a result of the expense of treatment, the extended timeframe needed for effective treatment, and the scarcity of medicines in some developing countries, patient compliance with TB treatment is very low and results in multi-drug resistant TB (MDR-TB). There remains a need for a faster, more effective treatment for TB. NCI researchers seek licensing and/or co-development of peptide inhibitors of STAT3 and IL-10 developed to treat bacterial infections such as tuberculosis. See aslo: NIH inventions E-164-2007 and E-167-2010
Researchers at the NCI have developed a vaccine technology that stimulates the immune system to selectively destroy metastasizing cells. Stimulation of T cells with the Brachyury peptide promote a robust immune response and lead to targeted lysis of invasive tumor cells. NCI seeks licensing or co-development of this invention.
The National Cancer Institute (NCI) seeks licensing and/or co-development research collaborations for a polymeric drug delivery platform that targets scavenger receptor A1 (SR-A1), a receptor highly expressed in macrophages, monocytes, mast cells, dendritic cells (myeloid lineages), and endothelial cells. The platform delivers various immunomodulatory therapeutic cargo including small molecule drugs, therapeutic peptides, and vaccines, to the lymphatic system and myeloid/antigen presenting cell (APC) sub-populations.
Natural products have long been considered a source of biologically active molecules against health disorders, including bone-loss related diseases. Cinnamolyoxy-mammeisin (CNM), can be isolated from Brazilian geopropolis and demonstrates anti-inflammatory activity. Researchers at the National Cancer Institute (NCI), in collaboration with researchers at the Piracicaba Dental School, University of Campinas, Brazil, have shown CNM also demonstrates inhibition of oral bone loss. This invention is available for licensing and/or co-development opportunities.
Researchers at the National Cancer Institute, Laboratory of Molecular Immunoregulation developed compositions and methods for using HMGN and its derivatives as immunoadjuvants with microbial or tumor antigens.The National Cancer Institute, Laboratory of Molecular Immunoregulation seeks parties interested in licensing or collaborative research to co-develop polypeptides or antagonists for immune response regulation.